Phase 3 Preterm infant Clinical Trials
8 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–8 of 8 trials
Recruiting
Phase 3
Intravenous pentoxifylline as adjunct therapy to improve long-term disability in preterm infants
Late-onset sepsis (LOS)Preterm infantsNecrotising enterocolitis (NEC)+1 more
University of Sydney1,800 enrolled25 locationsACTRN12616000405415
Completed
Phase 3
MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: Neuroprotection Trial
Complications of preterm infantCerebral PalsyNeuroprotection
University of Adelaide1,676 enrolled1 locationACTRN12611000491965
Completed
Phase 3
Randomised trial of dopamine vs dobutamine for treatment of low systemic blood flow in very preterm infants
Low systemic blood flow in preterm infants
A/Prof Nick Evans45 enrolled1 locationACTRN12607000152426
Terminated
Phase 3
BOOST II: Benefits Of Oxygen Saturation Targeting Study
Preterm infants
NHMRC Clinical Trials Centre1,200 enrolled1 locationACTRN12605000055606
Completed
Phase 3
Optimising very preterm infant outcomes: an evidence based screening and surveillance method
Disability of very preterm infant
The University of Queensland202 enrolled1 locationACTRN12606000472572
Completed
Phase 3
The DINO Trial
Preterm Infants < or = 32 weeks
National Health and Medical Research Council640 enrolled1 locationACTRN12606000327583
Completed
Phase 3
Skin exposure during conventional phototherapy in preterm infants: A Randomised Controlled Trial
Preterm infants with physiological jaundice
The University of Queensland60 enrolled1 locationACTRN12606000474550
Completed
Phase 3
The Benefits of Oxygen Saturation Targeting (BOOST) trial: different oxygen levels for preterm infants
Preterm infants
Centre for Perinatal Health Services Research, University of Sydney358 enrolled1 locationACTRN12606000375550